Ferroprotinl表达与乳腺癌发生、侵袭及预后的关系  

Effects of Ferroprotin 1 expression on tumorigenesis, invasiveness and survival of patients with breast cancer

作　　者：宋传贵[1] 吴雪英[1] 傅芳萌[1] 康德勇[2] 王川[1] 

机构地区：[1]福建医科大学附属协和医院乳腺外科,福州350001 [2]福建医科大学附属协和医院病理科,福州350001

出　　处：《中华普通外科杂志》2012年第6期471-474,共4页Chinese Journal of General Surgery

基　　金：基金项目：福建省自然科学基金资助项目（2006J0096）;福建省教育厅基金资助项目（JA11120）

摘　　要：目的探讨Ferroprotinl的表达在乳腺癌发生中的作用及与乳腺癌患者临床病理特征及预后的关系。方法采用免疫组织化学方法对100例有完整随访资料的乳腺癌患者的石蜡包埋组织进行Ferroprotinl蛋白的表达分析，探讨其在癌和癌旁正常组织中的表达差异，以及其表达水平和乳腺癌临床病理参数及预后的潜在关系。结果在乳腺癌旁正常组织中，Ferroprotinl高表达者为37例（37／100，37％），高于癌组织的24例（24／100，24％），χ2=3．986，P=0．046。发生腋窝淋巴结转移的乳腺癌患者中，Ferroprotinl低表达的比例明显高于高表达组，分别为36／40（90％），4／40（10％），差异有统计学意义（P=0．007）；在TNM分期中，Fermpmtinl低表达组在Ⅱ期以上的比例明显高于高表达组，其中Ⅲ期为44／57（77．2％），Ⅳ期为17／18（94．4％），P=0．05；未发现组织分级、肿瘤大小、激素受体表达、HER2表达情况及组织类型与Ferroprotinl表达之间存在明显的相关性（P〉0．05）。生存分析发现，Ferroprotinl低表达组患者中位生存时问为94．1个月；Ferroprotinl高表达组患者中位生存时间为96．8个月，差异无统计学意义（X2=0．289，P=0．591）。结论Ferroprotin1是促进乳腺癌发生的潜在因素；Ferroprotin1表达促进淋巴结转移，增加侵袭性，伴随较晚分期，是疾病进展的危险因素，但可能不是影响预后的重要因素。Objective To explore the effect of Ferroprotin 1 expression on tumorigenesis, invasiveness and survival of breast cancer. Methods In this study, 100 breast cancer patients were enrolled. IHC SP was used to detect the expression of Ferroprotinl in paraffin-embedded tissues. The association of Ferroprotin 1 expression and clinieo-pathologieal parameters was evaluated by ehi-square test. Survival analysis was calculated by Kaplan-Meier model and Log-rank test. Results The expression of Ferroprotin 1 was significantly higher in para-cancerous normal tissues （37/100, 37% ） than that in breast cancer tissues （24/100, 24% ; P =0. 046）. In these with positive axillary LN, there were more with low expression level of Ferroprotin 1 （ 36/40,90% ） than those with high expression level （ 4/40, 10% ）, P = 0. 007. More patients with low Ferroprotinl were at advanced stage than those with high ferroprotinl [ Ⅲ 44/57（77.2% ） ; IV 17/18 （ 94. 4% ） ] （ P = 0. 05 ）. No significant association was found between ferroprotinl and tumor grade, histology type, ER/PR, HER2, tumor size （P 〉0. 05）. Ferroprotinl has no significant effect on breast cancer survival （ P = 0. 591 ） by Kaplan-Meier curve and Log-rank test. Conclusions Low Ferroprotin 1 may lead to the tumorigenesis of breast cancer. Downregulated Ferroprotinl promotes the LN involvement of breast cancer and accompanies with more advanced disease. However Ferroprotinl might not play an important role in the survival of breast cancer.

关 键 词：乳腺肿瘤 免疫组织化学 预后 膜铁转运蛋白1 

分 类 号：R737.9[医药卫生—肿瘤]